Managed Healthcare Executive

Managed Healthcare Executive offers healthcare leaders in health plans and provider organizations valuable analysis, insights, and strategies aimed at achieving value-focused solutions.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#539869

United States

#170751

Health/Health

#3290

Traffic sources

Monthly visitors

Articles

FDA Approves Dupixent for Inflammatory Skin Disease

6 days ago | managedhealthcareexecutive.com | Denise Myshko

The FDA has approved the resubmitted application of Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU). It is indicated for patients who remain symptomatic despite histamine-1 (H1) antihistamine treatment. Chronic spontaneous urticaria is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.
FDA Sets Action Date for Eylea HD in Retinal Vein Occlusion

1 week ago | managedhealthcareexecutive.com | Denise Myshko

The FDA has accepted for priority review Regeneron’s supplemental biologics license application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The sBLA seeks approval for Eylea HD to treat patients with macular edema following retinal vein occlusion (RVO), and for broadening the dosing schedule to include every 4-week (monthly) dosing across approved indications. The FDA's target action date is Aug.
Medicaid Expansion Linked To Timelier Lung Cancer Surgery and Access to High-Volume Hospitals

1 week ago | managedhealthcareexecutive.com | Patricia Weiser

Patients with early-stage lung cancer were more likely to receive timely surgery and be treated at high-volume hospitals if they lived in a state that expanded Medicaid under the Affordable Care Act, according to a new study conducted by researchers at MD Anderson Cancer Center in Houston. The research was published last week in The Annals of Thoracic Surgery.
MRI Imaging May Be Important Biomarker in DMD

1 week ago | managedhealthcareexecutive.com | Jared Kaltwasser

Magnetic resonance imaging (MRI) appears to be able to meaningfully track functional changes in Duchenne muscular dystrophy (DMD), according to a recent analysis. If validated in additional studies, MRI-based biomarkers could become a surrogate endpoint in future trials involving patients with DMD, the study suggests. The findings were published in Muscle & Nerve. The study was sponsored by Pfizer Inc. and AMRA Medical. Lead author Sarah P.
UnitedHealth Group’s First Quarter Revenue Increases, But Company Revises Outlook

1 week ago | managedhealthcareexecutive.com | Denise Myshko

UnitedHealth Group’s first quarter 2025 revenue has grown compared with the first quarter of 2024, but the company has adjusted its performance outlook for 2025 to net earnings of $24.65 to $25.15 per share. Company leaders said in a press release that healthcare expenses, especially physician and outpatient services, within the Medicare Advantage businesses were above what they had expected.
Verve’s One-Time Gene Editor Cuts LDL by Nearly 70% in Early Trial

1 week ago | managedhealthcareexecutive.com | Ryan Flinn

A one-time gene editing treatment by Verve Therapeutics reduced low-density lipoprotein (LDL) cholesterol by nearly 70% in patients with inherited or premature cardiovascular disease, according to early clinical trial results released this week. In the phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 led to a mean LDL reduction of 53% among patients receiving the highest dose, with the maximum individual reduction reaching 69%, the company said in a news release.
Obesity and Use of GLP-1 Drugs are Increasing in People with Type 1 Diabetes

1 week ago | managedhealthcareexecutive.com | Denise Myshko

The use of GLP-1 receptor agonists rose in patients who have type 1 diabetes as obesity rates increased for these patients, according to a new study published online in Diabetes, Obesity and Metabolism. In the highest obesity category assessed by researchers, the proportion of adult patients using these medications increased from about 4% in the 2008 to 2011 period to about 33% in the 2020 to 2023 timeframe.
Long-Term Corticosteroids Benefit Motor, Respiratory Function in Duchenne Patients

1 week ago | managedhealthcareexecutive.com | Jared Kaltwasser

A new meta-analysis of longitudinal studies supports the use of corticosteroids as a means to preserve motor and respiratory function in patients with Duchenne muscular dystrophy (DMD). The analysis, however, found the benefits are less clear in terms of cardiac outcomes. The findings were presented in an abstract at the Muscular Dystrophy Association’s 2025 Clinical and Scientific Conference, held last month in Dallas. Lead author Mahmoud M.
Analysis Finds Brukinsa May Provide Costs Savings Over Imbruvica in CLL

1 week ago | managedhealthcareexecutive.com | Denise Myshko

The use of Brukinsa (zanubrutinib) instead of Imbruvica (ibrutinib) as a second-line treatment for patients with chronic lymphocytic leukemia could potentially lead to fewer adverse events and result in fewer healthcare costs, according to new analysis. This analysis, using a number needed to treat (NNT) modeling method, estimated that approximately 13 patients would avoid disease progression or death over 24 months, saving about $4.7 million.
Protein Responsible for Parkinson’s Disease Also Drives Melanoma Progression

1 week ago | managedhealthcareexecutive.com | Ryan Flinn

Researchers have uncovered a surprising mechanism linking Parkinson’s disease and melanoma, potentially explaining why people with one condition face higher risks of developing the other. The culprit: a protein called alpha-synuclein that plays dramatically different roles in neurons versus skin cancer cells.